ArticleHuman cell2011
BnRCH gene inhibits cell growth of Hela cells through increasing the G2 phase of cell cycle.
Article in Human cell, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed, 2 citations in OpenAlex.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The ubiquitin-proteasome pathway (UPP) is an important protein degradation system universally existing in eukaryotic organisms from yeast to human. In this system, hundreds of E3 ubiquitin-protein ligases are most important because they provide the substrate specificity and control many cellular processes. UPP has been found to be relevant to cancer development. BnRCH, the protein product from a novel gene isolated from Brassica napus, also has E3 ubiquitin-protein ligase activity. In order to exploit its potential use, human cervical carcinoma cell Hela (Hela cells) was transiently and stably transfected with BnRCH. The experimental results demonstrated: (1) in Hela cells, BnRCH inhibited the cell growth of Hela cells and increased their sensitivity to the anti-cancer chemotherapeutic drug cisplatin; and (2) the growth inhibition effect of BnRCH in Hela cells was found due to G2 phase cell cycle arrest with the transcriptional up-regulation of p21 (waf1/cip1), rather than apoptosis. This research suggests BnRCH has potential use in cancer therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.